Volume 23, Number 8—August 2017
California Serogroup Virus Infection Associated with Encephalitis and Cognitive Decline, Canada, 2015
Highlight and copy the desired format.
|EID||Webster D, Dimitrova K, Holloway K, Makowski K, Safronetz D, Drebot M, et al. California Serogroup Virus Infection Associated with Encephalitis and Cognitive Decline, Canada, 2015. Emerg Infect Dis. 2017;23(8):1423-1424. https://dx.doi.org/10.3201/eid2308.170239|
|AMA||Webster D, Dimitrova K, Holloway K, et al. California Serogroup Virus Infection Associated with Encephalitis and Cognitive Decline, Canada, 2015. Emerging Infectious Diseases. 2017;23(8):1423-1424. doi:10.3201/eid2308.170239.|
|APA||Webster, D., Dimitrova, K., Holloway, K., Makowski, K., Safronetz, D., & Drebot, M. (2017). California Serogroup Virus Infection Associated with Encephalitis and Cognitive Decline, Canada, 2015. Emerging Infectious Diseases, 23(8), 1423-1424. https://dx.doi.org/10.3201/eid2308.170239.|
California serogroup (CSG) viruses, such as Jamestown Canyon and snowshoe hare viruses, are mosquitoborne pathogens that cause febrile illness and neurologic disease. Human exposures have been described across Canada, but infections are likely underdiagnosed. We describe a case of neuroinvasive illness in a New Brunswick, Canada, patient infected with a CSG virus.
California serogroup (CSG) viruses (family Bunyaviridae, genus Orthobunyavirus) (1) include the mosquitoborne pathogens Jamestown Canyon virus (JCV), snowshoe hare virus (SSHV), and La Crosse virus. Competent vectors include non-Culex mosquitoes (e.g., Aedes, Culiseta, and Anopheles species), all of which circulate in New Brunswick, Canada (2,3). The major reservoir and vertebrate amplifier of JCV is believed to be the white-tailed deer (4). Squirrels, chipmunks, and hares serve as vertebrate reservoirs for SSHV (5). CSG virus infection is generally asymptomatic; however, after an incubation period of 3–7 days, a febrile illness may develop, and central nervous system involvement may lead to encephalitis or meningoencephalitis (6). No targeted therapies exist; treatment is supportive.
We describe a previously independent 73-year-old man, living on Grand Manan Island, off the Fundy Coast of southern New Brunswick, with a febrile illness that began July 23, 2015. The man was hospitalized, and the next day he exhibited abnormal behaviors (purposeless movements and incoherent speech) and became increasingly confused. The confusion and fever continued to worsen, and headache and neck pain developed. On July 28, he was treated with ceftriaxone and transferred to a tertiary-care hospital (Saint John Regional Hospital, Saint John, New Brunswick), where ampicillin and acyclovir were administered. Cerebral spinal fluid values were as follows: leukocyte count, 1 × 106 cells/L (reference range 0–5 × 106 cells/L); glucose, 3.5 mmol/L (reference range 2.2–3.9 mmol/L); and protein concentration, 0.58 g/L (reference range 0.15–0.45 g/L). On July 30, an infectious diseases specialist diagnosed the patient with viral encephalitis, most likely secondary to herpes simplex virus infection; ceftriaxone and ampicillin were discontinued. At a neurology consultation on July 31, the patient was still febrile and confused; brain magnetic resonance imaging revealed no acute pathology.
On August 4, additional information revealed that the patient went on frequent excursions into the woods of Grand Manan Island and had exposures to feral cats. Doxycycline was initiated, and serologic tests were conducted for Bartonella, Borrelia, Coxiella, and Anaplasma species and for Powassan virus, JCV, and SSHV; tests were also conducted to rule out paraneoplastic process and autoimmune causes. By August 12, the patient was afebrile but remained confused. On August 18, PCR was negative for herpes simplex virus in CSF, and an electroencephalograph revealed no periodic lateralizing epileptiform discharges; acyclovir was discontinued. Initial serologic test results were negative, and the patient showed no autoimmune or paraneoplastic markers. During a geriatric assessment, the patient showed persistent delirium, scoring 13/30 on a mini–mental state examination.
On August 21, we received the patient’s initial CSG serology results and collected follow-up serum samples for standard serologic testing by IgM capture ELISA and plaque-reduction neutralization testing (PRNT) (7,8). The acute-phase serum sample was IgM-negative but positive for CSG virus–specific neutralizing antibodies by PRNT (Table). Serial convalescent-phase serum specimens demonstrated IgM seroconversion several weeks after symptom onset and a >4-fold rise in PRNT titers for JCV and SSHV, indicating a diagnostic rise. Because serum neutralization titers for both viruses were equivalent or, at most, demonstrated only a 2-fold difference, the specific CSG virus associated with the patient’s illness could not be determined. Confirmatory PRNT titers for both viruses and the absence of IgM in the acute-phase serum suggest prior exposure to a CSG virus associated with the etiologic pathogen in this case. Secondary infections with orthobunyaviruses may result in a gradual or delayed rise in IgM, with neutralizing antibodies already detectable early after symptom onset, as documented in other cases involving CSG viruses (9).
Results for all other serologic tests were negative, leading to a modification of the diagnosis to confirmed CSG viral encephalitis. On September 9, the patient was transferred to a nursing home. In January 2016, further assessment revealed a lower mini–mental state examination score of 11/30. The patient, who was totally dependent for personal care and instrumental activities of daily living, was diagnosed with postencephalitic dementia.
Exposures to CSG viruses have been documented in New Brunswick (5; M.A. Drebot, unpub. data), and serologic results described in this report suggest that the patient may have been infected by JCV or SSHV on 2 different occasions. Human seroprevalence of CSG virus, specifically JCV, has been noted to be high in the maritime provinces of Atlantic Canada. A serosurvey in Nova Scotia identified an overall CSG seroprevalence of 21.2% (95% CI 16.1%–27.0%) (10). As such, there is need for increased awareness that these viruses are circulating during the mosquito season and may be associated with human disease.
Although most CSG infections result in mild illness, this case further highlights that these viruses can cause severe and debilitating neuroinvasive disease. Patients who seek medical care for febrile or encephalitic clinical symptoms and who have possible or known exposures to mosquito vectors should be considered for CSG virus testing. JCV and SSHV infection should be considered in the differential diagnosis for such patients during the spring, summer, and fall.
Dr. Webster is an infectious diseases consultant and medical microbiologist at the Saint John Regional Hospital and an associate professor in the Faculty of Medicine at Dalhousie University in Saint John, New Brunswick, Canada. His primary research interests include zoonoses, harm reduction, tuberculosis, and glycosylation.
- Bente DA. California encephalitis, hantavirus pulmonary syndrome, and bunyavirus hemorrhagic fevers. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases, 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 2025–30.
- LeDuc JW. Epidemiology and ecology of the California serogroup viruses. Am J Trop Med Hyg. 1987;37(Suppl):60S–8S.
- Webster RP, Giguère M, Maltais P, Roy J, Gallie L, Edsall J. Survey of the mosquitoes of New Brunswick. Government of New Brunswick. January 25, 2004 [cited 2016 Dec 5]. http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/CDC/MosquitoeSurvey.pdf
- Andreadis TG, Anderson JF, Armstrong PM, Main AJ. Isolations of Jamestown Canyon virus (Bunyaviridae: Orthobunyavirus) from field-collected mosquitoes (Diptera: Culicidae) in Connecticut, USA: a ten-year analysis, 1997-2006. Vector Borne Zoonotic Dis. 2008;8:175–88.
- Drebot MA. Emerging mosquito-borne bunyaviruses in Canada. Can Commun Dis Rep. 2015;41-06:117–23 [cited 2016 Dec 5]. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-06/ar-01-eng.php
- Artsob H. Arbovirus activity in Canada. In: Calisher CH, editor. Hemorrhagic fever with renal syndrome, tick- and mosquito-borne viruses. Archives of Virology Supplementum, vol 1. Vienna: Springer; 1990.
- Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol. 2000;38:1823–6.
- Beaty BJ, Calisher CH, Shope RS. Diagnostic procedures for viral, rickettsial and chlamydial infections. In: Schmidt NJ, Emmons RW, editors. 6th ed. Diagnostic procedures for viral, rickettsial and chlamydial infections. Washington (DC): American Public Health Association; 1989. p. 797–856.
- Rogstad DK, Schiffman E, Neitzel D, Baddour LM. Severe sepsis caused by California serogroup orthobunyavirus. Emerg Infect Dis. 2015;21:1876–7.
- Patriquin G, Schleihauf E, Johnston BL, Dimitrova K, Mask A, Traykova-Andonova M, et al. Seroprevalence of Jamestown Canyon virus in Nova Scotia. Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2016;1:18–9 https://www.ammi.ca/Annual-Conference/2016/Abstracts/2016%20JAMMI%20Abstracts.pdf.
- Table. Serologic test results for a patient with California serogroup virus infection associated with encephalitis and cognitive decline, Canada, 2015
Please use the form below to submit correspondence to the authors or contact them at the following address:
Duncan Webster, Dalhousie University, Faculty of Medicine, Division of Infectious Diseases, Department of Medicine, Saint John Regional Hospital, Saint John, NB E2L 4L2, Canada
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 17, 2017
- Page last updated: July 17, 2017
- Page last reviewed: July 17, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)